Core Insights - Abivax congratulates Victor Ambros and Gary Ruvkun for their Nobel Prize in Physiology or Medicine, recognizing their contributions to the understanding of microRNA and gene regulation [1][2] - The company emphasizes its commitment to innovative therapies utilizing microRNA, particularly through its lead candidate obefazimod, which is in advanced clinical trials for chronic inflammatory diseases [2][3] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [4] - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 trials for moderately to severely active ulcerative colitis and has shown positive results in Phase 2 trials [3][4] Product Development - Obefazimod is an orally administered small molecule that enhances the expression of microRNA-124 (miR-124), aimed at reducing inflammation in chronic inflammatory conditions [2][3] - The pivotal global Phase 3 clinical trial program (ABTECT Program) for ulcerative colitis began enrolling patients in October 2022, with a Phase 2b trial for Crohn's disease ongoing as of October 2024 [3]
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation